Mouse Fibroblast growth factor 23(FGF23) ELISA kit

Code CSB-EL008629MO
Size 96T,5×96T,10×96T How to order?
Trial Size 24T ELISA kits trial application
Have Questions? Leave a Message or Start an on-line Chat

Product Details


This Mouse FGF23 ELISA Kit was designed for the quantitative measurement of Mouse FGF23 protein in serum, plasma, tissue homogenates. It is a Sandwich ELISA kit, its detection range is 23.44 pg/mL-1500 pg/mL and the sensitivity is 5.86 pg/mL.

Target Name fibroblast growth factor 23
Alternative Names Fgf23Fibroblast growth factor 23 ELISA kit; FGF-23 ELISA kit
Abbreviation FGF23
Uniprot No. Q9EPC2
Species Mus musculus (Mouse)
Sample Types serum, plasma, tissue homogenates
Detection Range 23.44 pg/mL-1500 pg/mL
Sensitivity 5.86 pg/mL
Assay Time 1-5h
Sample Volume 50-100ul
Detection Wavelength 450 nm
Research Area Signal Transduction
Assay Principle quantitative
Measurement Sandwich
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
To assess the linearity of the assay, samples were spiked with high concentrations of mouse FGF23 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
  Sample Serum(n=4)
1:1 Average % 102
Range % 98-107
1:2 Average % 85
Range % 80-90
1:4 Average % 91
Range % 85-95
1:8 Average % 94
Range % 90-98
The recovery of mouse FGF23 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample Type Average % Recovery Range
Serum (n=5) 90 85-94
EDTA plasma (n=4) 97 93-101
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
pg/ml OD1 OD2 Average Corrected
1500 2.614 2.468 2.541 2.386
750 2.103 2.095 2.099 1.944
375 1.587 1.513 1.550 1.395
187.5 1.002 1.074 1.038 0.883
93.75 0.564 0.554 0.559 0.404
46.88 0.356 0.382 0.369 0.214
23.44 0.245 0.239 0.242 0.087
0 0.159 0.151 0.155  
ELISA Data Analysis Watch ELISA data processing video & download Curve Expert if needed
and FAQs
Storage Store at 2-8°C. Please refer to protocol.
Lead Time 3-5 working days

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

(From Uniprot)
Regulator of phosphate homeostasis. Inhibits renal tubular phosphate transport by reducing SLC34A1 levels. Acts directly on the parathyroid to decrease PTH secretion. Regulator of vitamin-D metabolism. Negatively regulates osteoblasts differentiation and matrix mineralization. Upregulates EGR1 expression in the presence of KL.
Gene References into Functions
  1. Increases in plasma erythropoietin and erythropoietin receptor activation are mechanisms implicated in the increase of plasma FGF23 in acute kidney injury. PMID: 29395333
  2. our data highlight a role of FGF23/FGFR4 signaling in the regulation of cardiac remodeling and function, and indicate that pharmacological interference with cardiac FGF23/FGFR4 signaling might protect from CKD- and age-related LVH. PMID: 28512310
  3. the main physiological function of Klotho for mineral homeostasis in vivo is its role as co-receptor mediating Fgf23 action. PMID: 28600880
  4. our study provided histological evidences that sclerostin tends to be secreted in osteocytes of remodeled mature bone, while FGF23 would be differently synthesized in osteoblasts and osteocytes according to the developmental stages PMID: 28794403
  5. these results indicate that Nf1 deficiency in osteocytes dramatically increases FGF23 production and causes a mineralization defect (ie, hyperosteoidosis) via the alteration of calcium-phosphorus metabolism. PMID: 28425622
  6. FGF23 promotes myocardial fibrosis and exacerbates diastolic dysfunction induced by myocardial infarction or ischemia/reperfusion , which is associated with the upregulation of active beta-catenin and TGF-beta PMID: 27579618
  7. deleting FGF23 within early osteoblasts and osteocytes demonstrated that both cell types contribute to baseline circulating FGF23 concentrations, and that targeting osteoblasts/osteocytes for FGF23 production can modify systemic responses to changes in serum phosphate concentrations and rescue the Hyp genetic syndrome PMID: 26792657
  8. Thus, monotherapy with 1,25D improves growth, skeletal microarchitecture, and bone strength in the absence of phosphate supplementation despite enhancing FGF23 expression, demonstrating that 1,25D has direct beneficial effects on the skeleton in XLH, independent of its role in phosphate homeostasis PMID: 26751835
  9. Zinc13407541 also inhibited FGF-23 signaling in isolated renal tubules ex vivo and partially reversed the hypophosphatemic effects of excess FGF-23 in a mouse model. These chemical probes provide a platform to develop lead compounds to treat disorders caused by excess FGF-23. PMID: 27879395
  10. FGF23 may be an important modulator of PTH signaling in bone and kidney. PMID: 27498418
  11. EPO dependent regulation pathway of FGF23 gene expression PMID: 29073196
  12. can directly stimulate hepatic secretion of inflammatory cytokines PMID: 27457912
  13. Klotho in bone is crucial for inducing FGF23 production upon renal failure PMID: 28183805
  14. dietary iron content and chronic kidney disease affected FGF23 production and metabolism PMID: 27733366
  15. Dmp1 mutation creates a lower set point for extracellular phosphate and maintains it through the regulation of Fgf23 cleavage and expression PMID: 28005411
  16. Although FGF23 is present in the fetal circulation at levels that may equal adult values, and there is robust expression of FGF23 target genes in placenta and fetal kidneys, FGF23 itself is not an important regulator of fetal phosphorous metabolism. PMID: 27929669
  17. Annexin A7 deficiency upregulates FGF23 plasma levels, an effect paralleled by increased corticosterone plasma levels, as well as decreased 1,25(OH)2 D3 and PTH plasma levels. PMID: 27871077
  18. FGF23 regulates osteopontin secretion indirectly by suppressing alkaline phosphatase transcription and phosphate production in osteoblastic cells, acting through FGF receptor-3 in a Klotho-independent manner PMID: 26235988
  19. AHSG is produced in bone, mainly in osteocytes and also show for the first time that its production is modulated by FGF23. PMID: 26476373
  20. Data suggest that Fgf23 level in serum is up-regulated by three forms of exercise (acute exercise, exhaustive exercise, and chronic exercise); however, only chronic exercise up-regulates FGF23 mRNA and protein expression in skeletal muscle. PMID: 27085781
  21. Data suggest that signal transduction via Fgf23/Fgfr1 and calcitriol/calcitriol receptor have opposite roles in innate immunity; Fgf23 suppresses arginase-1 expression in macrophages; calcitriol stimulates arginase-1 expression in macrophages. PMID: 26762170
  22. results link CYP24 activity to the pathophysiology of FGF23-dependent renal phosphate wasting states and implicate pharmacologic CYP24 inhibition as a therapeutic adjunct for their treatment. PMID: 26784541
  23. Although the molecular link between the cardiac lesion and circulating Fgf23 concentrations remains to be identified, our study has uncovered a novel heart-bone-kidney axis PMID: 25858796
  24. Akt/PKB/SGK-sensitive GSK3 inhibition participates in the regulation of FGF23 release, 1,25(OH)2D3 formation, and thus mineral metabolism, by controlling the activity of the sympathetic nervous system. PMID: 26527066
  25. our data demonstrate that the effect of FGF23 on Pi homeostasis is mediated, at least in part, by activation of egr-1. PMID: 26588476
  26. Activation of FGFR1 is essential for the high levels of FGF23 in acute and chronic experimental uremia. PMID: 26311115
  27. findings revealed that FGF23 neutralization effectively improves bone quality and osseointegration of titanium implants in CKD mice, suggesting FGF23 as a key factor of CKD related bone diseases. PMID: 25665715
  28. the FGF23 proximal promoter harbors cis elements that drive responsiveness to 1,25D and calcium, agents that induce FGF23 to curtail the pathologic consequences of their excess. PMID: 26148725
  29. ctivation of autocrine/paracrine FGF pathways is involved in the pathogenesis of Hyp through FGFR1-dependent regulation of FGF23 by both transcriptional and post-transcriptional mechanisms. PMID: 25089825
  30. Normalization of serum FGF23 levels by did not abrogate the aggravated cardiac hypertrophy observed in Klotho-deficient chronic kidney disease. PMID: 25475745
  31. Fgf23-deficient mice are profoundly deaf. They have moderate hearing loss above 20 kHz, consistent with mixed conductive and sensorineural pathology of both middle and inner ear origin. these mice demonstrate dysplastic bulla and ossicles. PMID: 25243481
  32. Increased levels of circulating FGF23 in pathological conditions such as Hyp mice exerts direct effects on the placenta and affects fetal vitamin D metabolism. PMID: 24470103
  33. The polycystic kidney produces FGF23 but is resistant to its action. PMID: 24402093
  34. Fgf23- and Klotho-deficient mice show renal Na+ wasting and are hypovolemic. PMID: 24797667
  35. The stabilized Fgf23-autosomal dominant hypophosphatemic rickets allele reversed the Galnt3-null phenotype and normalized total Fgf23, serum phosphorus, and bone Fgf23 mRNA. PMID: 25051439
  36. High levels of FGF23 contribute to cardiovascular dysfunction. PMID: 25053401
  37. phosphate levels contribute in part to the high OPN levels in Fgf23(-/-) mice PMID: 24038141
  38. Circulating FGF23 level is increased in early chronic kidney disease (CKD) and is expressed in the vascular media of sham-operated mice; its expression is decreased in early CKD. PMID: 23884339
  39. disturbed iron and oxygen metabolism in neonatal life may have important effects on skeletal function and structure through FGF23 activity on phosphate regulation. PMID: 23873717
  40. FGF-23 is unlikely to have major effects on cardiovascular structure and function. PMID: 24525546
  41. The presence of Klotho-independent FGF23 effects in a Klotho-expressing target organ represents a paradigm shift in the conceptualization of FGF23 endocrine action PMID: 24348262
  42. Failed to find support for FGF23-mediated catabolism of vitamin D metabolites in chronic kidney disease assessed by 24,25(OH)(2)D levels. PMID: 22739976
  43. FGF23 directly affects the differentiation of bone marrow stromal cells PMID: 24068282
  44. P2Y13 receptor regulates phosphate metabolism and FGF-23 secretion with effects on skeletal development PMID: 24487286
  45. Data (including data from mutant/transgenic mice) suggest that FGF23 is not an important regulator of fetal phosphorous metabolism; active delivery of phosphorus across the placenta does not require FGF23. PMID: 24601885
  46. a novel role for FGF-23 in erythrocyte production and differentiation and suggest that elevated FGF-23 levels contribute to the pathogenesis of anemia PMID: 24509850
  47. observed a 3- to 10-fold increase in CYP27B1 mRNA abundance in the lung, spleen, aorta and testis of FGF-23 null/1alpha-Luc mice PMID: 24019880
  48. FGF23, not alphaKlotho, is a calcium-conserving hormone in the kidney. PMID: 24434184
  49. regulation of skeletal Fgf23 expression by sympathetic activity is dependent on the circadian clock system and may shed light on new regulatory networks of FGF23 PMID: 24302726
  50. High FGF23 variability in dialysis patients is mainly associated with lower baseline serum phosphorus. PMID: 23635517

Show More

Hide All

Subcellular Location Secreted.
Protein Families Heparin-binding growth factors family
Tissue Specificity Mainly expressed in the brain and thymus at low levels. In brain; preferentially expressed in the ventrolateral thalamic nucleus.
Database Links

KEGG: mmu:64654

STRING: 10090.ENSMUSP00000000186

UniGene: Mm.347933

Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
7505 Fannin St. Ste 610-312, Houston, TX 77054, USA
Join Us with

Subscribe newsletter

Leave a message

© 2007-2022 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1